UBS analyst Ashwani Verma lowered the firm’s price target on Coherus Biosciences (CHRS) to $1.05 from $1.50 and keeps a Neutral rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences CCO Resigns After UDENYCA Divestiture
- Coherus Biosciences Completes UDENYCA Franchise Divestiture
- Coherus Biosciences completes divestiture of UDENYCA franchise
- Coherus Biosciences announces repurchase of $170M of convertible notes
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue